| 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 测试业务(WuXi Testing)(元) | - | - | 5,670,738,410.03 | 3,018,355,999.39 |
| 国内新药研发服务部(WuXi DDSU)(元) | - | - | - | 257,177,952.01 |
| 化学业务(WuXi Chemistry)(元) | - | - | 29,052,409,079.42 | 12,209,866,826.82 |
| 生物学业务(WuXi Biology)(元) | - | - | 2,543,926,320.99 | 1,168,909,867.67 |
| 细胞及基因疗法CTDMO业务(WuXi ATU)(元) | - | - | - | 574,952,553.89 |
| 终止经营业务(元) | 2,035,342,035.35 | 394,179,009.52 | 1,323,649,163.45 | - |
| 测试业务(WuXiTesting)(元) | 4,041,701,030.67 | 2,688,647,220.66 | - | - |
| 化学业务(WuXiChemistry)(元) | 36,465,846,882.97 | 16,301,370,405.46 | - | - |
| 生物学业务(WuXiBiology)(元) | 2,677,175,030.51 | 1,251,604,868.49 | - | - |
| 其他业务(元) | - | 163,480,378.33 | 650,708,385.99 | - |
| 其他业务(Others)(元) | 236,100,794.68 | - | - | - |
| 营业成本(元) | ||||
| 测试业务(WuXi Testing)(元) | - | - | 3,814,644,625.35 | 1,959,376,484.09 |
| 国内新药研发服务部(WuXi DDSU)(元) | - | - | - | 106,846,974.62 |
| 化学业务(WuXi Chemistry)(元) | - | - | 15,574,099,540.41 | 6,889,155,768.40 |
| 生物学业务(WuXi Biology)(元) | - | - | 1,584,978,592.32 | 747,196,887.66 |
| 细胞及基因疗法CTDMO业务(WuXi ATU)(元) | - | - | - | 745,749,242.37 |
| 终止经营业务(元) | 1,616,503,499.07 | 344,069,097.45 | 1,536,931,193.83 | - |
| 测试业务(WuXiTesting)(元) | 2,859,258,619.77 | 2,024,256,847.97 | - | - |
| 化学业务(WuXiChemistry)(元) | 17,542,535,781.54 | 8,302,923,339.92 | - | - |
| 生物学业务(WuXiBiology)(元) | 1,749,326,228.58 | 813,008,608.78 | - | - |
| 其他业务(元) | - | 69,866,314.78 | 453,861,508.71 | - |
| 其他业务(Others)(元) | 33,810,428.98 | - | - | - |
| 毛利(元) | ||||
| 测试业务(WuXi Testing)(元) | - | - | 1,856,093,784.68 | 1,058,979,515.30 |
| 国内新药研发服务部(WuXi DDSU)(元) | - | - | - | 150,330,977.39 |
| 化学业务(WuXi Chemistry)(元) | - | - | 13,478,309,539.01 | 5,320,711,058.42 |
| 生物学业务(WuXi Biology)(元) | - | - | 958,947,728.67 | 421,712,980.01 |
| 细胞及基因疗法CTDMO业务(WuXi ATU)(元) | - | - | - | -170,796,688.48 |
| 终止经营业务(元) | 418,838,536.28 | 50,109,912.07 | -213,282,030.38 | - |
| 测试业务(WuXiTesting)(元) | 1,182,442,410.90 | 664,390,372.69 | - | - |
| 化学业务(WuXiChemistry)(元) | 18,923,311,101.43 | 7,998,447,065.54 | - | - |
| 生物学业务(WuXiBiology)(元) | 927,848,801.93 | 438,596,259.71 | - | - |
| 其他业务(元) | - | 93,614,063.55 | 196,846,877.28 | - |
| 其他业务(Others)(元) | 202,290,365.70 | - | - | - |
| 毛利率(%) | ||||
| 测试业务(WuXi Testing)(%) | - | - | 32.73 | 35.08 |
| 国内新药研发服务部(WuXi DDSU)(%) | - | - | - | 58.45 |
| 化学业务(WuXi Chemistry)(%) | - | - | 46.39 | 43.58 |
| 生物学业务(WuXi Biology)(%) | - | - | 37.70 | 36.08 |
| 细胞及基因疗法CTDMO业务(WuXi ATU)(%) | - | - | - | -29.71 |
| 终止经营业务(%) | 20.58 | 12.71 | -16.11 | - |
| 测试业务(WuXiTesting)(%) | 29.26 | 24.71 | - | - |
| 化学业务(WuXiChemistry)(%) | 51.89 | 49.07 | - | - |
| 生物学业务(WuXiBiology)(%) | 34.66 | 35.04 | - | - |
| 其他业务(%) | - | 57.26 | 30.25 | - |
| 其他业务(Others)(%) | 85.68 | - | - | - |
| 收入构成(%) | ||||
| 测试业务(WuXi Testing)(%) | - | - | 14.45 | 17.52 |
| 国内新药研发服务部(WuXi DDSU)(%) | - | - | - | 1.49 |
| 化学业务(WuXi Chemistry)(%) | - | - | 74.04 | 70.87 |
| 生物学业务(WuXi Biology)(%) | - | - | 6.48 | 6.78 |
| 细胞及基因疗法CTDMO业务(WuXi ATU)(%) | - | - | - | 3.34 |
| 终止经营业务(%) | 4.48 | 1.90 | 3.37 | - |
| 测试业务(WuXiTesting)(%) | 8.89 | 12.93 | - | - |
| 化学业务(WuXiChemistry)(%) | 80.22 | 78.37 | - | - |
| 生物学业务(WuXiBiology)(%) | 5.89 | 6.02 | - | - |
| 其他业务(%) | - | 0.79 | 1.66 | - |
| 其他业务(Others)(%) | 0.52 | - | - | - |
| 毛利构成(%) | ||||
| 测试业务(WuXi Testing)(%) | - | - | 11.40 | 15.62 |
| 国内新药研发服务部(WuXi DDSU)(%) | - | - | - | 2.22 |
| 化学业务(WuXi Chemistry)(%) | - | - | 82.81 | 78.47 |
| 生物学业务(WuXi Biology)(%) | - | - | 5.89 | 6.22 |
| 细胞及基因疗法CTDMO业务(WuXi ATU)(%) | - | - | - | -2.52 |
| 终止经营业务(%) | 1.93 | 0.54 | -1.31 | - |
| 测试业务(WuXiTesting)(%) | 5.46 | 7.19 | - | - |
| 化学业务(WuXiChemistry)(%) | 87.39 | 86.51 | - | - |
| 生物学业务(WuXiBiology)(%) | 4.28 | 4.74 | - | - |
| 其他业务(%) | - | 1.01 | 1.21 | - |
| 其他业务(Others)(%) | 0.93 | - | - | - |